Evidence map›Paper›PMID 32363327›Full record

ArticleJournal of laboratory and precision medicine2020

GlycA: A New Biomarker for Systemic Inflammation and Cardiovascular Disease (CVD) Risk Assessment.

Rami A Ballout, Alan T Remaley

Open access · diamondAbstract read
In one paragraph

Article in Journal of laboratory and precision medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 82 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Association of Glycoprotein Acetylation With Carotid-Femoral Pulse Wave Velocity in Patients Receiving Maintenance Hemodialysis.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Lifestyles, metabolome and diabetic kidney disease: a cohort study.QJM : monthly journal of the Association of Physicians · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rami A BalloutLipoprotein Metabolism Section, Translational and Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD, USA.
Alan T RemaleyLipoprotein Metabolism Section, Translational and Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD, USA.
National Heart Lung and Blood Institute · US

Funding

Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeuticZIAHL006092 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI REMALEY, ALAN THOMAS · 2010 to 2021
$13.0M
Intramural NIH HHS ZIA HL006092
6 · The paper itself

Abstract

The GlycA test is a recently developed proton nuclear magnetic resonance (

Indexed as

acute phase reactantsatherosclerosiscoronary artery diseaseGlycAhsCRPN-glycans

Identifiers

PMID32363327
PMCPMC7194207
OpenAlexW3014339295

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.